{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:16:53Z","timestamp":1778285813209,"version":"3.51.4"},"reference-count":183,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012654","name":"Olga Mayenfisch Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012654","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"publisher","award":["MEDEF-20-021"],"award-info":[{"award-number":["MEDEF-20-021"]}],"id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.bbr.2022.114174","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T02:16:32Z","timestamp":1666404992000},"page":"114174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["PET imaging in animal models of Parkinson\u2019s disease"],"prefix":"10.1016","volume":"438","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0793-2113","authenticated-orcid":false,"given":"Ruiqing","family":"Ni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2022.114174_bib1","doi-asserted-by":"crossref","unstructured":"Global, regional, and national burden of Parkinson's disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet Neurol., 17, 2018, pp. 939\u2013953. \u3008DOI: 10.1016\/s1474-4422(18)30295-3\u3009.","DOI":"10.1016\/S1474-4422(18)30295-3"},{"key":"10.1016\/j.bbr.2022.114174_bib2","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.bbr.2022.114174_bib3","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrneurol.2014.205","article-title":"Neuroimaging in Parkinson disease: from research setting to clinical practice","volume":"10","author":"Politis","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bbr.2022.114174_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.tins.2018.09.007","article-title":"Triggers, facilitators, and aggravators: redefining Parkinson's disease pathogenesis","volume":"42","author":"Johnson","year":"2019","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib5","first-page":"1073","article-title":"Parkinson's disease drug therapies in the clinical trial pipeline: 2022 update","volume":"12","author":"McFarthing","year":"2022","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.bbr.2022.114174_bib6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nrg1831","article-title":"Genetics of Parkinson disease: paradigm shifts and future prospects","volume":"7","author":"Farrer","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bbr.2022.114174_bib7","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jnr.10231","article-title":"Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters","volume":"68","author":"Rockenstein","year":"2002","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bbr.2022.114174_bib8","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.bbr.2022.114174_bib9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0896-6273(02)00682-7","article-title":"Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein","volume":"34","author":"Giasson","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.bbr.2022.114174_bib10","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1073\/pnas.132197599","article-title":"Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice","volume":"99","author":"Lee","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbr.2022.114174_bib11","doi-asserted-by":"crossref","first-page":"35104","DOI":"10.1074\/jbc.M111.247965","article-title":"E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment","volume":"286","author":"Emmer","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbr.2022.114174_bib12","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1523\/JNEUROSCI.20-16-06021.2000","article-title":"Neuropathology in mice expressing human alpha-synuclein","volume":"20","author":"van der Putten","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1006\/nbdi.2001.0392","article-title":"Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter","volume":"8","author":"Matsuoka","year":"2001","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbr.2022.114174_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.expneurol.2012.11.007","article-title":"Expression of human E46K-mutated \u03b1-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment","volume":"240","author":"Cannon","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbr.2022.114174_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","article-title":"LRRK2 in Parkinson disease: challenges of clinical trials","volume":"16","author":"Tolosa","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bbr.2022.114174_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018568","article-title":"Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2","volume":"6","author":"Ramonet","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbr.2022.114174_bib17","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nn.2349","article-title":"Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease","volume":"12","author":"Li","year":"2009","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40478-017-0413-0","article-title":"Propagation of pathological \u03b1-synuclein in marmoset brain","volume":"5","author":"Shimozawa","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.bbr.2022.114174_bib19","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bbr.2022.114174_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.bbr.2022.114174_bib21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00401-019-02037-5","article-title":"Oral and intravenous transmission of \u03b1-synuclein fibrils to mice","volume":"138","author":"Lohmann","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbr.2022.114174_bib22","doi-asserted-by":"crossref","first-page":"E8284","DOI":"10.1073\/pnas.1710442114","article-title":"Modeling Parkinson's disease pathology by combination of fibril seeds and \u03b1-synuclein overexpression in the rat brain","volume":"114","author":"Thakur","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbr.2022.114174_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nprot.2006.342","article-title":"Protocol for the MPTP mouse model of Parkinson's disease","volume":"2","author":"Jackson-Lewis","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bbr.2022.114174_bib24","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.celrep.2015.01.060","article-title":"Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism","volume":"10","author":"Osterberg","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbr.2022.114174_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.nbd.2013.04.017","article-title":"A novel \u03b1-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of \u03b1-synuclein-GFP","volume":"56","author":"Hansen","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbr.2022.114174_bib26","doi-asserted-by":"crossref","unstructured":"A. Caputo, Y. Liang, T.D. Raabe, A. Lo, M. Horvath, B. Zhang, et al., Snca-GFP knock-in mice reflect patterns of endogenous expression and pathological seeding, eNeuro, 2020, p. 7:ENEURO.0007-0020.2020. \u3008DOI: 10.1523\/ENEURO.0007-20.2020\u3009.","DOI":"10.1523\/ENEURO.0007-20.2020"},{"key":"10.1016\/j.bbr.2022.114174_bib27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00259-019-04488-0","article-title":"Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development","volume":"47","author":"McCluskey","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bbr.2022.114174_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.771982","article-title":"Recent technical advances in accelerating the clinical translation of small animal brain imaging: hybrid imaging, deep learning, and transcriptomics","volume":"9","author":"Ren","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.bbr.2022.114174_bib29","article-title":"Current progress in the development of probes for targeting \u03b1-synuclein aggregates","author":"Zeng","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib30","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fnagi.2021.751897","article-title":"Recent developments in positron emission tomography tracers for proteinopathies imaging in dementia","volume":"13","author":"Ni","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib31","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00259-020-05133-x","article-title":"[(11)C]MODAG-001-towards a PET tracer targeting \u03b1-synuclein aggregates","volume":"48","author":"Kuebler","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bbr.2022.114174_bib32","first-page":"25","article-title":"PET radiopharmaceuticals for Alzheimer's disease and Parkinson's disease diagnosis, the current and future landscape","author":"Uzuegbunam","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bbr.2022.114174_bib33","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1021\/acs.molpharmaceut.8b00229","article-title":"In silico, in vitro, and in vivo evaluation of new candidates for \u03b1-synuclein PET imaging","volume":"15","author":"Verdurand","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbr.2022.114174_bib34","unstructured":"M. Ono, M. Takahashi, A. Shimozawa, M. Fujinaga, W. Mori, Y. Nagai, et al., In Vivo Visualization of Propagating \u03b1-Synuclein Pathologies in Mouse and Marmoset Models by A Bimodal Imaging Probe, C05-C05, 2020."},{"key":"10.1016\/j.bbr.2022.114174_bib35","doi-asserted-by":"crossref","unstructured":"N. Raval, C. Madsen, V. Shalgunov, A. Nasser, U. Battisti, E. Beaman, et al., Evaluation of the \u03b1-Synuclein PET Radiotracer (d3)-[11C]MODAG-001 in Pigs, 2022.","DOI":"10.21203\/rs.3.rs-1268531\/v1"},{"key":"10.1016\/j.bbr.2022.114174_bib36","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1038\/s41598-021-82037-2","article-title":"Synthesis and pharmacokinetic characterisation of a fluorine-18 labelled brain shuttle peptide fusion dimeric affibody","volume":"11","author":"Morito","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbr.2022.114174_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.108985","article-title":"In vivo imaging of alpha-synuclein with antibody-based PET","author":"Roshanbin","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2022.114174_bib38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41583-019-0220-7","article-title":"Believing in dopamine","volume":"20","author":"Gershman","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib39","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.2967\/jnumed.119.239418","article-title":"Confirmation of (123)I-FP-CIT SPECT quantification methods in dementia with lewy bodies and other neurodegenerative disorders","volume":"61","author":"Maltais","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbr.2022.114174_bib40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neurobiolaging.2021.07.012","article-title":"Monitoring of a progressive functional dopaminergic deficit in the A53T-AAV synuclein rats by combining 6-[(18)F]fluoro-L-m-tyrosine imaging and motor performances analysis","volume":"107","author":"Becker","year":"2021","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbr.2022.114174_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065286","article-title":"Construction and evaluation of quantitative small-animal PET probabilistic atlases for [\u00b9\u2078F]FDG and [\u00b9\u2078F]FECT functional mapping of the mouse brain","volume":"8","author":"Casteels","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbr.2022.114174_bib42","doi-asserted-by":"crossref","unstructured":"S. S\u00e9rri\u00e8re, A. Dom\u00e9n\u00e9, J. Vercouillie, C. Mothes, S. Bodard, N. Rodrigues, et al., Assessment of the protection of dopaminergic neurons by an \u03b17 nicotinic receptor agonist, PHA 543613 using [(18)F]LBT-999 in a Parkinson's disease rat model, Front. Med., 2, 2015, p. 61. \u3008DOI: 10.3389\/fmed.2015.00061\u3009.","DOI":"10.3389\/fmed.2015.00061"},{"key":"10.1016\/j.bbr.2022.114174_bib43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2967\/jnumed.111.101436","article-title":"In vivo dopamine transporter imaging in a unilateral 6-hydroxydopamine rat model of Parkinson disease using 11C-methylphenidate PET","volume":"53","author":"Sossi","year":"2012","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbr.2022.114174_bib44","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1046\/j.1460-9568.2002.01938.x","article-title":"Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging","volume":"15","author":"Cicchetti","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib45","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2967\/jnumed.106.037796","article-title":"Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats","volume":"48","author":"Pellegrino","year":"2007","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbr.2022.114174_bib46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.expneurol.2013.06.002","article-title":"AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model","volume":"248","author":"Ren","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbr.2022.114174_bib47","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.neuropharm.2015.11.010","article-title":"Functional modulation of G-protein coupled receptors during Parkinson disease-like neurodegeneration","volume":"108","author":"Jenkins","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2022.114174_bib48","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2967\/jnumed.115.169615","article-title":"PET imaging of mitochondrial complex I with 18F-BCPP-EF in the brains of MPTP-treated monkeys","volume":"57","author":"Tsukada","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbr.2022.114174_bib49","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1471-4159.2007.05108.x","article-title":"VMAT2 and dopamine neuron loss in a primate model of Parkinson\u2019s disease","volume":"105","author":"Chen","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbr.2022.114174_bib50","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.apradiso.2012.08.005","article-title":"Evaluation of dopamine transporters and D2 receptors in hemiparkinsonian rat brains in vivo using consecutive PET scans of [18F]FPCIT and [18F]fallypride","volume":"70","author":"Choi","year":"2012","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.bbr.2022.114174_bib51","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2967\/jnumed.116.189159","article-title":"Effect of MPTP on serotonergic neuronal systems and mitochondrial complex I activity in the living brain: a PET study on conscious rhesus monkeys","volume":"58","author":"Kanazawa","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbr.2022.114174_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146301","article-title":"Voluntary exercise delays progressive deterioration of markers of metabolism and behavior in a mouse model of Parkinson\u2019s disease","volume":"1720","author":"Lai","year":"2019","journal-title":"Brain Res."},{"key":"10.1016\/j.bbr.2022.114174_bib53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1523\/JNEUROSCI.2289-15.2016","article-title":"Dynamic changes in striatal mGluR1 but not mGluR5 during pathological progression of Parkinson's disease in human alpha-synuclein A53T transgenic rats: a multi-PET imaging study","volume":"36","author":"Yamasaki","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib54","article-title":"N-acetylcysteine decreases dopamine transporter availability in the non-lesioned striatum of the 6-OHDA hemiparkinsonian rat","author":"Virel","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbr.2022.114174_bib55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.nucmedbio.2015.11.002","article-title":"PET imaging of dopamine transporters with [(18)F]FE-PE2I: effects of anti-Parkinsonian drugs","volume":"43","author":"Bang","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.bbr.2022.114174_bib56","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1177\/0271678X17750351","article-title":"Evaluation of exercise-induced modulation of glial activation and dopaminergic damage in a rat model of Parkinson's disease using [(11)C]PBR28 and [(18)F]FDOPA PET","volume":"39","author":"Real","year":"2019","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.bbr.2022.114174_bib57","article-title":"Imaging of cerebral tryptophan metabolism using 7-[(18)F]FTrp-PET in a unilateral Parkinsonian rat model","volume":"247","author":"Endepols","year":"2021","journal-title":"Neuroimage"},{"key":"10.1016\/j.bbr.2022.114174_bib58","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/jcbfm.2012.120","article-title":"In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET","volume":"33","author":"Walker","year":"2013","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.bbr.2022.114174_bib59","doi-asserted-by":"crossref","unstructured":"M.D. Walker, M. Volta, S. Cataldi, K. Dinelle, D. Beccano-Kelly, L. Munsie, et al., Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging, J. Parkinsons Dis., 4, 2014, pp. 483\u2013498. \u3008DOI: 10.3233\/jpd-140344\u3009.","DOI":"10.3233\/JPD-140344"},{"key":"10.1016\/j.bbr.2022.114174_bib60","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1523\/JNEUROSCI.2010-15.2016","article-title":"Imaging dopamine and serotonin systems on MPTP Monkeys: a longitudinal PET investigation of compensatory mechanisms","volume":"36","author":"Ballanger","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib61","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1172\/JCI21137","article-title":"Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model","volume":"115","author":"Takagi","year":"2005","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbr.2022.114174_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/mds.29051","article-title":"Dopaminergic positron emission tomography imaging in the alpha-synuclein preformed fibril model reveals similarities to early Parkinson's disease","author":"Sossi","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2022.114174_bib63","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4","article-title":"In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease","volume":"47","author":"Lee","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbr.2022.114174_bib64","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuroimage.2005.09.044","article-title":"Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study","volume":"30","author":"Doudet","year":"2006","journal-title":"Neuroimage"},{"key":"10.1016\/j.bbr.2022.114174_bib65","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/jnc.14681","article-title":"PET imaging of dopamine release in the frontal cortex of manganese-exposed non-human primates","volume":"150","author":"Guilarte","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbr.2022.114174_bib66","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/syn.10070","article-title":"Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP-treated monkeys: PET studies with [11C]raclopride","volume":"44","author":"Doudet","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.bbr.2022.114174_bib67","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0022-510X(95)00137-Q","article-title":"Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride","volume":"132","author":"Rinne","year":"1995","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbr.2022.114174_bib68","first-page":"969","article-title":"Fasudil promotes \u03b1-synuclein clearance in an AAV-mediated \u03b1-synuclein rat model of Parkinson's disease by autophagy activation","volume":"10","author":"Yang","year":"2020","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.bbr.2022.114174_bib69","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ana.24066","article-title":"Lewy body extracts from Parkinson disease brains trigger \u03b1-synuclein pathology and neurodegeneration in mice and monkeys","volume":"75","author":"Recasens","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbr.2022.114174_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039041","article-title":"PET imaging a MPTP-induced mouse model of Parkinson\u2019s disease using the fluoropropyl-dihydrotetrabenazine analog [18F]-DTBZ (AV-133)","volume":"7","author":"Toomey","year":"2012","journal-title":"PLOS ONE"},{"key":"10.1016\/j.bbr.2022.114174_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173503","article-title":"Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson\u2019s disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging","volume":"12","author":"Weng","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.bbr.2022.114174_bib72","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s13311-021-01018-5","article-title":"Neuroprotection of exendin-4 by enhanced autophagy in a Parkinsonian rat model of \u03b1-synucleinopathy","volume":"18","author":"Bu","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bbr.2022.114174_bib73","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1038\/s41598-017-06724-9","article-title":"Early synaptic dysfunction induced by \u03b1-synuclein in a rat model of Parkinson\u2019s disease","volume":"7","author":"Phan","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbr.2022.114174_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2020.08.002","article-title":"PET imaging with [18F]FP-(+)-DTBZ in 6-OHDA-induced partial and full unilaterally-lesioned model rats of Parkinson's disease and the correlations to the biological data","volume":"90\u201391","author":"Tang","year":"2020","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.bbr.2022.114174_bib75","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.nbd.2015.01.007","article-title":"Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study","volume":"77","author":"Molinet-Dronda","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbr.2022.114174_bib76","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ardp.201300307","article-title":"Synthesis and biological evaluation of 10-(11) C-dihydrotetrabenazine as a vesicular monoamine transporter 2 radioligand","volume":"347","author":"Li","year":"2014","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bbr.2022.114174_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105229","article-title":"PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats","volume":"149","author":"Thomsen","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbr.2022.114174_bib78","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-021-01257-1","article-title":"Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys","volume":"27","author":"Tao","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbr.2022.114174_bib79","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1021\/acschemneuro.1c00651","article-title":"PET imaging of VMAT2 with the novel radioligand [18F]FE-DTBZ-d4 in nonhuman primates: comparison with [11C]DTBZ and [18F]FE-DTBZ","volume":"12","author":"Nag","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib80","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.nucmedbio.2010.01.006","article-title":"In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease","volume":"37","author":"Wang","year":"2010","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.bbr.2022.114174_bib81","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3727\/096368912X658683","article-title":"PET imaging of serotonin transporters with 4-[18F]-ADAM in a Parkinsonian rat model","volume":"22","author":"Weng","year":"2013","journal-title":"Cell Transpl."},{"key":"10.1016\/j.bbr.2022.114174_bib82","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/cns.12978","article-title":"PET imaging of the influence of physiological and pathological \u03b1-synuclein on dopaminergic and serotonergic neurotransmission in mouse models","volume":"25","author":"Levigoureux","year":"2019","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.bbr.2022.114174_bib83","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2967\/jnumed.115.163683","article-title":"In vivo evaluation of 11C-DASB for quantitative SERT imaging in rats and mice","volume":"57","author":"Walker","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbr.2022.114174_bib84","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbr.2022.114174_bib85","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.trci.2017.08.004","article-title":"Measuring brain synaptic vesicle protein 2A with positron emission tomography and [18F]UCB-H","volume":"3","author":"Bahri","year":"2017","journal-title":"Alzheimer's Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.bbr.2022.114174_bib86","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2967\/jnumed.120.249144","article-title":"First-in-human evaluation of (18)F-SynVesT-1, a radioligand for PET imaging of synaptic vesicle glycoprotein 2A","volume":"62","author":"Naganawa","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbr.2022.114174_bib87","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acschemneuro.8b00526","article-title":"Synthesis and in vivo evaluation of a novel PET radiotracer for imaging of synaptic vesicle glycoprotein 2A (SV2A) in nonhuman primates","volume":"10","author":"Li","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib88","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11307-018-1260-5","article-title":"Development and in vivo preclinical imaging of fluorine-18-labeled synaptic vesicle protein 2A (SV2A) PET tracers","volume":"21","author":"Constantinescu","year":"2019","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.bbr.2022.114174_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2021.118302","article-title":"In vivo imaging of synaptic density with [11C]UCB-J PET in two mouse models of neurodegenerative disease","volume":"239","author":"Xiong","year":"2021","journal-title":"NeuroImage"},{"key":"10.1016\/j.bbr.2022.114174_bib90","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/0271678X20931140","article-title":"In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET","volume":"41","author":"Thomsen","year":"2021","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"27","key":"10.1016\/j.bbr.2022.114174_bib91","article-title":"Synaptic density and neuronal metabolic function measured by PET in the unilateral 6-OHDA rat model of Parkinson\u2019s disease","volume":"05","author":"Raval","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.bbr.2022.114174_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(21)00377-X","article-title":"Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches","author":"Bohnen","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbr.2022.114174_bib93","first-page":"26","article-title":"[(18)F]Nifene PET\/CT imaging in mice: improved methods and preliminary studies of \u03b14\u03b22* nicotinic acetylcholinergic receptors in transgenic A53T mouse model of \u03b1-synucleinopathy and post-mortem human Parkinson's disease","author":"Campoy","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bbr.2022.114174_bib94","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neuroimage.2017.05.066","article-title":"Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia","volume":"157","author":"Zhou","year":"2017","journal-title":"Neuroimage"},{"key":"10.1016\/j.bbr.2022.114174_bib95","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s11307-020-01485-w","article-title":"Evaluation of the neuroprotective effect of microglial depletion by CSF-1R inhibition in a Parkinson's animal model","volume":"22","author":"Oh","year":"2020","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.bbr.2022.114174_bib96","doi-asserted-by":"crossref","first-page":"7938","DOI":"10.7150\/thno.47585","article-title":"Evaluation of (18)F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration in vivo in rodents and in human tissue","volume":"10","author":"Lepelletier","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bbr.2022.114174_bib97","first-page":"1","article-title":"Inflammation and immune dysfunction in Parkinson disease","author":"Tansey","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbr.2022.114174_bib98","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12974-018-1171-z","article-title":"Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration","volume":"15","author":"Duffy","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.bbr.2022.114174_bib99","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1038\/s41467-021-26519-x","article-title":"Microglia-specific overexpression of \u03b1-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity","volume":"12","author":"Bido","year":"2021","journal-title":"Nat. Commun."},{"issue":"5089\u2013106","key":"10.1016\/j.bbr.2022.114174_bib100","article-title":"Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes","volume":"184","author":"Scheiblich","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bbr.2022.114174_bib101","doi-asserted-by":"crossref","unstructured":"P. Krashia, A. Cordella, A. Nobili, L. La Barbera, M. Federici, A. Leuti, et al., Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease, Nat. Commun., 10, 2019, p. 3945. \u3008DOI: 10.1038\/s41467-019-11928-w\u3009.","DOI":"10.1038\/s41467-019-11928-w"},{"key":"10.1016\/j.bbr.2022.114174_bib102","article-title":"PET imaging of neuroinflammation in Alzheimer's disease","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbr.2022.114174_bib103","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.neurobiolaging.2007.11.005","article-title":"PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET","volume":"30","author":"Venneti","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbr.2022.114174_bib104","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/glia.22978","article-title":"In vivo imaging of microglial activation by positron emission tomography with [(11)C]PBR28 in the 5XFAD model of Alzheimer's disease","volume":"64","author":"Mirzaei","year":"2016","journal-title":"Glia"},{"key":"10.1016\/j.bbr.2022.114174_bib105","doi-asserted-by":"crossref","first-page":"10957","DOI":"10.1523\/JNEUROSCI.0673-07.2007","article-title":"Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography","volume":"27","author":"Maeda","year":"2007","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib106","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1177\/0271678X16677990","article-title":"Brain energy metabolism and neuroinflammation in ageing APP\/PS1-21 mice using longitudinal (18)F-FDG and (18)F-DPA-714 PET imaging","volume":"37","author":"Takkinen","year":"2017","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.bbr.2022.114174_bib107","doi-asserted-by":"crossref","first-page":"954","DOI":"10.2967\/jnumed.115.167858","article-title":"Glial activation and glucose metabolism in a transgenic amyloid mouse model: a triple-tracer PET study","volume":"57","author":"Brendel","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbr.2022.114174_bib108","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1212\/01.WNL.0000078192.95645.E6","article-title":"11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy","volume":"61","author":"Gerhard","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2022.114174_bib109","doi-asserted-by":"crossref","first-page":"e1592","DOI":"10.1212\/WNL.0000000000009249","article-title":"In vivo mitochondrial and glycolytic impairments in patients with Alzheimer disease","volume":"94","author":"Terada","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2022.114174_bib110","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S1474-4422(17)30173-4","article-title":"Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study","volume":"16","author":"Stokholm","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbr.2022.114174_bib111","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1007\/s00259-020-04772-4","article-title":"[(18)F]-DPA-714 PET as a specific in vivo marker of early microglial activation in a rat model of progressive dopaminergic degeneration","volume":"47","author":"Rodr\u00edguez-Chinchilla","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bbr.2022.114174_bib112","doi-asserted-by":"crossref","DOI":"10.1002\/syn.22060","article-title":"In vivo quantification of glial activation in minipigs overexpressing human \u03b1-synuclein","volume":"72","author":"Lillethorup","year":"2018","journal-title":"Synapse"},{"key":"10.1016\/j.bbr.2022.114174_bib113","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00259-018-4161-6","article-title":"PET imaging of [(11)C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding","volume":"46","author":"Varn\u00e4s","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bbr.2022.114174_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105027","article-title":"Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: a case series","volume":"144","author":"Joers","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbr.2022.114174_bib115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pneurobio.2016.04.006","article-title":"Microglial phenotypes in Parkinson's disease and animal models of the disease","volume":"155","author":"Joers","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bbr.2022.114174_bib116","doi-asserted-by":"crossref","DOI":"10.1111\/cei.13649","article-title":"imaging of the dynamic phenotypes of microglia","author":"Beaino","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbr.2022.114174_bib117","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3389\/fnins.2019.00799","article-title":"Increased P2X7 receptor binding is associated with neuroinflammation in acute but not chronic rodent models for Parkinson\u2019s disease","volume":"13","author":"Crabb\u00e9","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib118","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.tins.2017.04.001","article-title":"The role of astrocyte dysfunction in Parkinson's disease pathogenesis","volume":"40","author":"Booth","year":"2017","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib119","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00259-015-3047-0","article-title":"Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study","volume":"42","author":"Rodriguez-Vieitez","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bbr.2022.114174_bib120","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3233\/JAD-201344","article-title":"In vitro characterization of the regional binding distribution of amyloid PET tracer florbetaben and the glia tracers deprenyl and PK11195 in autopsy Alzheimer's brain tissue","volume":"80","author":"Ni","year":"2021","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.bbr.2022.114174_bib121","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/brain\/awz260","article-title":"Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo11C-BU99008 PET study","volume":"142","author":"Wilson","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2022.114174_bib122","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2967\/jnumed.120.244400","article-title":"(18)F-SMBT-1: a selective and reversible PET tracer for monoamine oxidase-B imaging","volume":"62","author":"Harada","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbr.2022.114174_bib123","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2967\/jnumed.116.183152","article-title":"Metabolic imaging in Parkinson disease","volume":"58","author":"Meles","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbr.2022.114174_bib124","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2020-324823","article-title":"Early atypical signs and insula hypometabolism predict survival in multiple system atrophy","author":"Grimaldi","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbr.2022.114174_bib125","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/jcbfm.2011.166","article-title":"Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism","volume":"32","author":"Ma","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.bbr.2022.114174_bib126","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.jcbfm.9600358","article-title":"Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility","volume":"27","author":"Ma","year":"2007","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.bbr.2022.114174_bib127","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1038\/s41598-019-42074-4","article-title":"Effect of genotype and age on cerebral [18F]FDG uptake varies between transgenic APPSwe-PS1dE9 and Tg2576 mouse models of Alzheimer\u2019s disease","volume":"9","author":"Snellman","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbr.2022.114174_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105669","article-title":"Cerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolism","volume":"167","author":"Molinet-Dronda","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbr.2022.114174_bib129","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3389\/fnins.2021.676257","article-title":"[18F]FDG PET\/CT studies in transgenic Hualpha-Syn (A53T) Parkinson\u2019s disease mouse model of \u03b1-synucleinopathy","volume":"15","author":"Mondal","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.112964","article-title":"Temporal changes in neuroinflammation and brain glucose metabolism in a rat model of viral vector-induced \u03b1-synucleinopathy","volume":"320","author":"Crabb\u00e9","year":"2019","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbr.2022.114174_bib131","doi-asserted-by":"crossref","first-page":"12368","DOI":"10.1038\/s41598-019-48713-0","article-title":"Identifying a glucose metabolic brain pattern in an adeno-associated viral vector based rat model for Parkinson\u2019s disease using 18F-FDG PET imaging","volume":"9","author":"Devrome","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbr.2022.114174_bib132","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.nbd.2016.08.010","article-title":"Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model","volume":"96","author":"Lerner","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbr.2022.114174_bib133","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","article-title":"The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease","volume":"85","author":"Pickrell","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.bbr.2022.114174_bib134","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1021\/acschemneuro.1c00297","article-title":"Novel positron emission tomography radiotracers for imaging mitochondrial complex I","volume":"12","author":"Xu","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib135","doi-asserted-by":"crossref","first-page":"eabj2658","DOI":"10.1126\/scitranslmed.abj2658","article-title":"Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease","volume":"14","author":"Jennings","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbr.2022.114174_bib136","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1039\/C9MD00590K","article-title":"Radiosynthesis and evaluation of 4-(6-[(18)F]Fluoro-4-(5-isopropoxy-1H-indazol-3-yl)pyridin-2-yl)morpholine as a novel radiotracer candidate targeting leucine-rich repeat kinase 2","author":"Mori","year":"2020","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bbr.2022.114174_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113005","article-title":"Development and biological evaluation of[(18)F]FMN3PA & [(18)F]FMN3PU for leucine-rich repeat kinase 2 (LRRK2) in vivo PET imaging","volume":"211","author":"Malik","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbr.2022.114174_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113245","article-title":"18F-Labelled pyrrolopyrimidines reveal brain leucine-rich repeat kinase 2 expression implicated in Parkinson\u2019s disease","volume":"214","author":"Chen","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbr.2022.114174_bib139","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.bmcl.2017.02.019","article-title":"Synthesis of [(11)C]HG-10-102-01 as a new potential PET agent for imaging of LRRK2 enzyme in Parkinson's disease","volume":"27","author":"Wang","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbr.2022.114174_bib140","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/cmdc.201900321","article-title":"Synthesis and preliminary evaluation of [(11) C]GNE-1023 as a potent PET probe for imaging leucine-rich repeat kinase\u20052 (LRRK2) in Parkinson's disease","volume":"14","author":"Chen","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbr.2022.114174_bib141","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40035-022-00289-y","article-title":"Pathophysiological significance of increased \u03b1-synuclein deposition in sympathetic nerves in Parkinson's disease: a post-mortem observational study","volume":"11","author":"Isonaka","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.bbr.2022.114174_bib142","article-title":"Cardiac alpha-synuclein is present in alpha-synucleinopathies","author":"Javanshiri","year":"2022","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.bbr.2022.114174_bib143","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S1474-4422(21)00219-2","article-title":"Parkinson's disease outside the brain: targeting the autonomic nervous system","volume":"20","author":"Sharabi","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbr.2022.114174_bib144","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1405-y","article-title":"Intestinal infection triggers Parkinson's disease-like symptoms in Pink1(-\/-) mice","volume":"571","author":"Matheoud","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2022.114174_bib145","doi-asserted-by":"crossref","unstructured":"J. Horsager, K.B. Andersen, K. Knudsen, C. Skj\u00e6rb\u00e6k, T.D. Fedorova, N. Okkels, et al., Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study, Brain, 143, 2020, pp. 3077\u20133088. \u3008DOI: 10.1093\/brain\/awaa238\u3009.","DOI":"10.1093\/brain\/awaa238"},{"key":"10.1016\/j.bbr.2022.114174_bib146","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","article-title":"Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson\u2019s disease","volume":"103","author":"Kim","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.bbr.2022.114174_bib147","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.121.263039","article-title":"Tracking innate immune activation in a mouse model of Parkinson's disease using TREM1 and TSPO pet tracers","author":"Lucot","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbr.2022.114174_bib148","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/brain\/awu369","article-title":"Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET","volume":"138","author":"Gjerl\u00f8ff","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2022.114174_bib149","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/mds.27698","article-title":"[(18) F]Fluoroethoxybenzovesamicol in Parkinson's disease patients: quantification of a novel cholinergic positron emission tomography tracer","volume":"34","author":"van der Zee","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2022.114174_bib150","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00259-016-3555-6","article-title":"Cholinergic PET imaging in infections and inflammation using (11)C-donepezil and (18)F-FEOBV","volume":"44","author":"J\u00f8rgensen","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bbr.2022.114174_bib151","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/mds.28387","article-title":"From iPS cells to rodents and nonhuman primates: filling gaps in modeling Parkinson's disease","volume":"36","author":"Outeiro","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2022.114174_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105184","article-title":"Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease","volume":"148","author":"Marmion","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbr.2022.114174_bib153","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","article-title":"Discriminating \u03b1-synuclein strains in Parkinson\u2019s disease and multiple system atrophy","volume":"578","author":"Shahnawaz","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2022.114174_bib154","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00401-020-02163-5","article-title":"Evidence of distinct \u03b1-synuclein strains underlying disease heterogeneity","volume":"142","author":"Holec","year":"2021","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbr.2022.114174_bib155","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1073\/pnas.1913904117","article-title":"The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration","volume":"117","author":"Mahul-Mellier","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbr.2022.114174_bib156","article-title":"Impact of \u03b1-synuclein spreading on the nigrostriatal dopaminergic pathway depends on the onset of the pathology","author":"Sun","year":"2021","journal-title":"Brain Pathol."},{"key":"10.1016\/j.bbr.2022.114174_bib157","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-05319-3","article-title":"Structures of \u03b1-synuclein filaments from human brains with Lewy pathology","author":"Yang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2022.114174_bib158","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41586-020-2317-6","article-title":"Structures of \u03b1-synuclein filaments from multiple system atrophy","volume":"585","author":"Schweighauser","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2022.114174_bib159","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1038\/s41467-022-32797-w","article-title":"The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils","volume":"13","author":"Antonschmidt","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbr.2022.114174_bib160","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ymthe.2003.09.013","article-title":"In vivo PET imaging of gene expression in Parkinsonian monkeys","author":"Eberling","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbr.2022.114174_bib161","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/mt.2010.106","article-title":"Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC","volume":"18","author":"Hadaczek","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbr.2022.114174_bib162","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s00259-007-0558-3","article-title":"Metabolic\u2013dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson\u2019s disease","volume":"35","author":"Casteels","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bbr.2022.114174_bib163","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s13287-020-01868-4","article-title":"Dopamine transporter neuroimaging accurately assesses the maturation of dopamine neurons in a preclinical model of Parkinson's disease","volume":"11","author":"Goggi","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.bbr.2022.114174_bib164","doi-asserted-by":"crossref","DOI":"10.1002\/syn.22077","article-title":"Extensive exploration of a novel rat model of Parkinson's disease using partial 6-hydroxydopamine lesion of dopaminergic neurons suggests new therapeutic approaches","volume":"73","author":"Vetel","year":"2019","journal-title":"Synapse"},{"key":"10.1016\/j.bbr.2022.114174_bib165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/brain\/aws358","article-title":"A progressive dopaminergic phenotype associated with neurotoxic conversion of \u03b1-synuclein in BAC-transgenic rats","volume":"136","author":"Nuber","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2022.114174_bib166","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.neuroimage.2012.06.051","article-title":"Imaging DA release in a rat model of L-DOPA-induced dyskinesias: a longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA","volume":"63","author":"Lettfuss","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.bbr.2022.114174_bib167","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2310\/7290.2012.00035","article-title":"In vivo visualization and monitoring of viable neural stem cells using noninvasive bioluminescence imaging in the 6-hydroxydopamine-induced mouse model of Parkinson disease","volume":"12","author":"Im","year":"2013","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.bbr.2022.114174_bib168","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/syn.21834","article-title":"Relationship between dopamine deficit and the expression of depressive behavior resulted from alteration of serotonin system","volume":"69","author":"Lee","year":"2015","journal-title":"Synapse"},{"key":"10.1016\/j.bbr.2022.114174_bib169","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jneumeth.2018.10.037","article-title":"A non-human primate model for stable chronic Parkinson\u2019s disease induced by MPTP administration based on individual behavioral quantification","volume":"311","author":"Seo","year":"2019","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.bbr.2022.114174_bib170","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1016\/j.neurobiolaging.2015.06.022","article-title":"Therapeutic potentials of human adipose-derived stem cells on the mouse model of Parkinson's disease","volume":"36","author":"Choi","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbr.2022.114174_bib171","first-page":"23","article-title":"[(18)F]fallypride-PET\/CT analysis of the dopamine D\u2082\/D\u2083 receptor in the hemiparkinsonian rat brain following intrastriatal botulinum neurotoxin A injection","author":"Mann","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bbr.2022.114174_bib172","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.nucmedbio.2012.04.003","article-title":"18F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2\/D3 receptor imaging in rat models of neurodegenerative diseases","volume":"39","author":"D\u00f6br\u00f6ssy","year":"2012","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.bbr.2022.114174_bib173","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090759","article-title":"Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease","volume":"9","author":"Sahin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbr.2022.114174_bib174","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1002\/mds.23407","article-title":"Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: In vivo imaging with [18F]fallypride","volume":"25","author":"Vu\u010dckovi\u0107","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2022.114174_bib175","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s11307-019-01418-2","article-title":"Imaging SERT availability in a rat model of L-DOPA-induced dyskinesia","volume":"22","author":"Walker","year":"2020","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.bbr.2022.114174_bib176","doi-asserted-by":"crossref","DOI":"10.3389\/fnsyn.2021.715811","article-title":"Synaptic density and neuronal metabolic function measured by positron emission tomography in the unilateral 6-OHDA rat model of Parkinson's disease","volume":"13","author":"Raval","year":"2021","journal-title":"Front. Synaptic Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib177","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11307-019-01400-y","article-title":"Longitudinal PET imaging of \u03b17 nicotinic acetylcholine receptors with [(18)F]ASEM in a rat model of Parkinson's disease","volume":"22","author":"Vetel","year":"2020","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.bbr.2022.114174_bib178","first-page":"25","article-title":"PET imaging of the adenosine A(2A) receptor in the rotenone-based mouse model of Parkinson's disease with [(18)F]FESCH synthesized by a simplified two-step one-pot radiolabeling strategy","author":"Schr\u00f6der","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bbr.2022.114174_bib179","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.nucmedbio.2011.01.009","article-title":"Striatal adenosine A(2A) receptor-mediated positron emission tomographic imaging in 6-hydroxydopamine-lesioned rats using [(18)F]-MRS5425","volume":"38","author":"Bhattacharjee","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.bbr.2022.114174_bib180","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12880-019-0375-8","article-title":"Development of a novel radioligand for imaging 18-kD translocator protein (TSPO) in a rat model of Parkinson's disease","volume":"19","author":"Wu","year":"2019","journal-title":"BMC Med. Imaging"},{"key":"10.1016\/j.bbr.2022.114174_bib181","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/j.1471-4159.2007.04690.x","article-title":"A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation","volume":"102","author":"Venneti","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbr.2022.114174_bib182","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/ejn.13232","article-title":"6-Hydroxydopamine-induced Parkinson's disease-like degeneration generates acute microgliosis and astrogliosis in the nigrostriatal system but no bioluminescence imaging-detectable alteration in adult neurogenesis","volume":"43","author":"Fricke","year":"2016","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbr.2022.114174_bib183","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.brainres.2009.12.026","article-title":"In vivo type 1 cannabinoid receptor mapping in the 6-hydroxydopamine lesion rat model of Parkinson's disease","volume":"1316","author":"Casteels","year":"2010","journal-title":"Brain Res."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432822004430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432822004430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T13:35:59Z","timestamp":1759066559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432822004430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":183,"alternative-id":["S0166432822004430"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2022.114174","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET imaging in animal models of Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2022.114174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114174"}}